BBHC
AQST icon

Brown Brothers Harriman & Co’s Aquestive Therapeutics AQST Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,100
Closed -$27 – 1152
2021
Q1 		$27 Buy
+5,100
New +$27.1K ﹤0.01% 739

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Brown Brothers Harriman & Co's AQST Position: Q2 2021 in Review

Brown Brothers Harriman & Co sold out of Aquestive Therapeutics (AQST) in Q2 2021, closing a stake of 5,100 shares — an estimated $27 sold.

Brown Brothers Harriman & Co first reported a position in AQST in Q1 2021 and held it in 1 quarter. The position peaked at $27 in Q1 2021. 60 funds tracked by Wall St. Rank hold AQST as of Q2 2021.

  • Brown Brothers Harriman & Co reported no remaining Aquestive Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 5,100 Aquestive Therapeutics shares in Q2 2021, an estimated $27.
  • Brown Brothers Harriman & Co first reported a position in Aquestive Therapeutics in Q1 2021 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Aquestive Therapeutics position peaked at $27 in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2021, filed 13 Aug 2021.